Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(147 productos)
- Bcr-Abl(103 productos)
- EGFR(572 productos)
- FAK(71 productos)
- FLT(91 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(169 productos)
- JAK(246 productos)
- PDGFR(126 productos)
- RAAS(87 productos)
- Src(80 productos)
- Syk(37 productos)
- Trombina(47 productos)
- VDA(2 productos)
- VEGFR(262 productos)
Mostrar 6 subcategorías más
Se han encontrado 1522 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
JGK-068S
CAS:<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Fórmula:C22H23BrFN5O2Pureza:98%Forma y color:SolidPeso molecular:488.35PAT-505
CAS:<p>PAT-505 is an autologous epidermal growth factor inhibitor.</p>Fórmula:C23H18ClF2N3O2SPureza:98.84%Forma y color:SolidPeso molecular:473.92BPR1J-340
CAS:<p>BPR1J-340, a novel potent FLT3 inhibitor, shows anticancer promise, with IC50 ~25 nM and GC50 ~5 nM, causing apoptosis in AML cells.</p>Fórmula:C29H34N8O3Forma y color:SolidPeso molecular:542.63Simotinib
CAS:Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.Fórmula:C25H26ClFN4O4Pureza:99.7%Forma y color:SolidPeso molecular:500.95BCR-ABL-IN-4
CAS:<p>BCR-ABL-IN-4: Anticancer BCR-ABL inhibitor; stops K562 cells (IC50: 0.67 nM), targets T315I Ba/F3 cells (IC50: 16 nM).</p>Fórmula:C27H24ClF2N5O4Forma y color:SolidPeso molecular:555.96TCJL37
CAS:<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Fórmula:C17H11ClF2N4O2Forma y color:SolidPeso molecular:376.74TAK-659
CAS:<p>TAK-659 is a spleen tyrosine kinase (SYK) inhibitor.</p>Fórmula:C17H21FN6OPureza:98%Forma y color:SolidPeso molecular:344.39MTP
CAS:<p>MTP, a PKM2 inhibitor, promotes apoptosis in cancer cells via caspase-3 activation while also inducing autophagy and enhancing ROS generation.</p>Fórmula:C29H23F3N4O2Pureza:98%Forma y color:SolidPeso molecular:516.51BTK-IN-11
CAS:<p>BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)</p>Fórmula:C26H22ClN5O3Forma y color:SolidPeso molecular:487.94SD 1008
CAS:<p>SD 1008 is a JAK2/STAT3 signaling pathway inhibitor. SD 1008 inhibits activation of STAT3, JAK2, and Src.</p>Fórmula:C18H19NO5Pureza:98%Forma y color:SolidPeso molecular:329.35SNIPER(TACC3)-11
CAS:<p>SNIPER(TACC3)-11 is a powerful FGFR3-TACC3 protein degrader, reducing its amount and hindering FGFR3-TACC3+ cancer cell growth.</p>Fórmula:C51H66N10O7S2Forma y color:SolidPeso molecular:995.26JAK-IN-24
CAS:<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Fórmula:C20H25N5O2Forma y color:SolidPeso molecular:367.44JAK-IN-17
<p>"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."</p>Fórmula:C33H38F2N6O8Forma y color:SolidPeso molecular:684.69BTK-IN-17
<p>BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.</p>Fórmula:C26H23N7O2Forma y color:SolidPeso molecular:465.51FLT3-IN-14
CAS:<p>FLT3-IN-14: FLT3 inhibitor; FLT3-WT IC50=5.6nM, FLT3-ITD IC50=1.4nM; blocks Y591 phosphorylation; G1 arrest; pro-apoptotic.</p>Fórmula:C25H24N6O2SForma y color:SolidPeso molecular:472.56ALK/EGFR-IN-1
CAS:<p>ALK/EGFR-IN-1 (Compound 8l) is a dual inhibitor targeting both ALK and EGFR, effectively blocking their phosphorylation.</p>Fórmula:C27H34ClN7O3SPureza:98%Forma y color:SolidPeso molecular:572.12BTK-IN-18
CAS:<p>BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.</p>Fórmula:C20H22Cl2N6OForma y color:SolidPeso molecular:433.33JAK-IN-26
CAS:<p>JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in</p>Fórmula:C22H24N6O3Pureza:98%Forma y color:SolidPeso molecular:420.46EGFR-IN-29
CAS:<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Fórmula:C36H46BrN8O2PForma y color:SolidPeso molecular:733.68Roslin 2 bromide
CAS:<p>Roslin 2 bromide (Benzylhexamethylenetetramine bromide) is a p53 reactivator that disrupts the binding of FAK and p5.</p>Fórmula:C13H19BrN4Pureza:99.34%Forma y color:SolidPeso molecular:311.22(Rac)-PF-06250112
CAS:<p>(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.</p>Fórmula:C22H20F2N6O2Pureza:98%Forma y color:SolidPeso molecular:438.43EVT801
CAS:<p>EVT801 is a highly selective and low-toxic VEGFR-3 inhibitor that inhibits VEGF-C-induced tumor lymphoid and angiogenesis and reduces CCL4, CCL5 and MDSC.</p>Fórmula:C19H21N5O3Pureza:97.4%Forma y color:SolidPeso molecular:367.4PF-303
CAS:<p>PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.</p>Fórmula:C22H21ClN6O2Forma y color:SolidPeso molecular:436.89HDAC-IN-50
CAS:<p>HDAC-IN-50, a potent FGFR/HDAC inhibitor (IC50: 0.18-13 nM), induces apoptosis, cell cycle arrest, and shows anti-tumor activity.</p>Fórmula:C31H41N7O4Forma y color:SolidPeso molecular:575.7MET kinase-IN-3
CAS:<p>MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.</p>Fórmula:C25H16ClF2N5O2Forma y color:SolidPeso molecular:491.88BTK-IN-19
CAS:<p>BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM .</p>Fórmula:C21H22Cl2N6OForma y color:SolidPeso molecular:445.35BTK inhibitor 20
CAS:<p>BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .</p>Fórmula:C37H42N8O4Forma y color:SolidPeso molecular:662.78Pivanex
CAS:<p>Pivanex, an oral HDAC inhibitor, targets metastasis, angiogenesis, reduces Bcr-Abl protein, and promotes apoptosis.</p>Fórmula:C10H18O4Pureza:≥98%Forma y color:SolidPeso molecular:202.25CP-547632 TFA
CAS:<p>CP-547632 TFA, an oral VEGFR-2 and FGF inhibitor, IC50: VEGFR-2 at 11 nM, FGF at 9 nM, shows antitumor activity.</p>Fórmula:C22H25BrF5N5O5SPureza:98%Forma y color:SolidPeso molecular:646.43HDAC/JAK/BRD4-IN-1
CAS:<p>HDAC/JAK/BRD4-IN-1 (compound 25ap) is a potent triple inhibitor targeting HDAC, JAK, and BRD4.</p>Fórmula:C24H28N6O3Pureza:98%Forma y color:SolidPeso molecular:448.52Tyk2-IN-9
CAS:<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Fórmula:C20H17N9Pureza:98%Forma y color:SolidPeso molecular:383.41EGFR-IN-36
CAS:<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Fórmula:C26H25ClN6O2Forma y color:SolidPeso molecular:488.97ALK/EGFR-IN-3
CAS:<p>ALK/EGFR-IN-3 is a dual ALK and EGFR inhibitor that demonstrates potent anti-proliferative effects on various cancer cell lines, including H1975, PC9, and Baf3-</p>Fórmula:C27H34ClN7O3SForma y color:SolidPeso molecular:572.12SG3-179
CAS:<p>SG3-179 is a BET inhibitor.</p>Fórmula:C28H35ClFN7O3SForma y color:SolidPeso molecular:604.14Infigratinib-Boc
CAS:<p>Infigratinib-Boc, a derivative of the ATP-competitive pan-FGFR inhibitor Infigratinib, incorporates a Boc (t-Butyloxy carbonyl) group [1].</p>Fórmula:C29H35Cl2N7O5Forma y color:SolidPeso molecular:632.54YS-363
CAS:<p>YS-363 is a potent, selective, and orally active inhibitor of the epidermal growth factor receptor (EGFR), exhibiting half-maximal inhibitory concentrations (</p>Fórmula:C30H30N4O3Pureza:98%Forma y color:SolidPeso molecular:494.58ALK/EGFR-IN-2
CAS:<p>ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells.</p>Fórmula:C27H34ClN7O3SForma y color:SolidPeso molecular:572.12EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Fórmula:C16H9ClIN3Forma y color:SolidPeso molecular:405.62JAK-IN-25
CAS:<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Fórmula:C19H17N5O4Pureza:98%Forma y color:SolidPeso molecular:379.37FLT3/ITD-IN-5
CAS:FLT3/ITD-IN-5 (Example 6) is an orally active inhibitor of both FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is utilized in cancer research.Fórmula:C23H25N7O2Forma y color:SolidPeso molecular:431.49HIF-2α-IN-1
CAS:<p>HIF-2α-IN-1 is a potent HIF-2α inhibitor with IC50 values less than 500 nM.</p>Fórmula:C16H8F5NO4SPureza:97.99%Forma y color:SolidPeso molecular:405.3JNJ-17029259
CAS:<p>JNJ-17029259 is an orally selective, potent inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2).</p>Fórmula:C26H30N6OPureza:98%Forma y color:SolidPeso molecular:442.56FGFR-IN-8
CAS:<p>FGFR-IN-8, potent oral FGFR inhibitor for wild-type/mutant types, induces apoptosis with anti-cancer properties.</p>Fórmula:C27H31Cl2N9O2Forma y color:SolidPeso molecular:584.5CHMFL-FLT3-122
CAS:<p>CHMFL-FLT3-122 is a potent and orally available FLT3 kinase inhibitor used to treat FLT3-ITD positive acute myeloid leukemia.</p>Fórmula:C26H29N7O2Pureza:99.63%Forma y color:SolidPeso molecular:471.55MS 154
CAS:MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.Fórmula:C46H54ClFN8O8Forma y color:SolidPeso molecular:901.42GSK2646264
CAS:<p>GSK2646264 (Compound 44) inhibits SYK (pIC50=7.1) and kinases like LCK, LRRK2; penetrates skin.</p>Fórmula:C24H26N2O2Forma y color:SolidPeso molecular:374.48Brolucizumab
CAS:<p>Brolucizumab (anti-VEGF-A scFv) potently blocks VEGF-A to reduce neovascularization in wet AMD, with picomolar binding affinity.</p>Pureza:95%Forma y color:LiquidJAK-IN-1
CAS:<p>JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.</p>Fórmula:C20H24N6O2Pureza:98%Forma y color:SolidPeso molecular:380.44ALK-IN-6
CAS:<p>ALK-IN-6 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK, IC50s: 71 nM, 18.72 nM, and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L).</p>Fórmula:C26H29ClD3N5O3SPureza:98%Forma y color:SolidPeso molecular:533.1Tubulin/JAK2-IN-1
CAS:<p>Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significant</p>Fórmula:C22H20N6O3Forma y color:SolidPeso molecular:416.43
